EVALUACIÓN PRECLÍNICA DE LIGANDOS DUALES PARA EL TRATAMIENTO DE LOS TRASTORNOS POR USO DE ALCOHOL

Resumen del proyecto

Alcohol Use Disorders are associated with a dramatic morbi-mortality, causing more than 3 millions of deaths in 2016, as the World Health Organization reports. Although there are some therapeutic tools for reducing alcohol consumption, their efficacy is partial, and there are social and medical barriers that precludes its wide utilization. In addition, the presence of alcohol-associated comorbidities (i.e. alcohol-liver disease or alcohol-induced cognitive imapirment and depression) results in an additional loss of efficacy of existing therapeutics and a high rate of therapeutic failure. There is an urgent need for developing drugs that might offer advantages by targetting the multimorbidity associated with alcohol abuse. The present project explores this idea by promoting the preclinical development of 4 molecules designed as multiple ligands with patented efficacy as reducers of alcohol intake. These compouds have a PPARa/CB1 (OLHHA), PPARa/PPARg (NF 10-360), PPARa/VR1 (N-Oleoylsulfamide) and PPARa/CB1/Antioxidant profile (HTLE).Applicant institution and researchers hold the intelectual property of these compounds, some of them included in patents P201830824 and P201830825 that covers OLHHA, NF10-360 and HTLE drugs as treatments for Alcohol Use Disorder. The present project intends to complete the preclinical development of these compounds through the a) Analysis of pharmacokinetics and toxicity of OLHHA, NF 10-360, N-oleoylsulfamide, and HTLE); b) To study the efficacy of these compounds as inhibitors of alcohol intake and alcohol seeking behavior; c) To study the efficacy of these compounds against alcohol-induced neuroinflammation, cognitive impairment and reduced neurogenesis. The ultimate objective will be to select one or two candidates to be promoted to clinical trials in humans through active licensing to or partnering with a pharmaceutical company.

Palabras clave

alcohol
abuso
farmacos
ligandos duales
preclinica
aciletanolamidas
biomarcadores
oleiletanolamida

Convocatoria

Acción Estratégica en Salud (AES)

Periodo de ejecución

01/01/2020 - 31/12/2021

Investigador Principal

RODRIGUEZ DE FONSECA, FERNANDO

Centro beneficiario

FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD (FIMABIS)

Centro de realización

INSTITUTO DE INVESTIGACION BIOMEDICA DE MALAGA (IBIMA)

Comunidad Autónoma

ANDALUCIA

Provincia

MALAGA

Financiación

103,400 €